Open | $1.580 |
Close | $1.500 |
Volume / Avg. | 52.513K / 111.077K |
Day Range | 1.500 - 1.580 |
52 Wk Range | 1.461 - 4.370 |
Market Cap | $26.017M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 40 |
Short Interest | % |
Days to Cover | 6.28 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Unity Biotechnology (NASDAQ: UBX) through any online brokerage.
Other companies in Unity Biotechnology’s space includes: Galecto (NASDAQ:GLTO), OncoCyte (NASDAQ:OCX), Lumos Pharma (NASDAQ:LUMO), Sensei Biotherapeutics (NASDAQ:SNSE) and Alaunos Therapeutics (NASDAQ:TCRT).
The latest price target for Unity Biotechnology (NASDAQ: UBX) was reported by Wedbush on Thursday, November 16, 2023. The analyst firm set a price target for 0.00 expecting UBX to fall to within 12 months (a possible -100.00% downside). 12 analyst firms have reported ratings in the last year.
The stock price for Unity Biotechnology (NASDAQ: UBX) is $1.55 last updated March 18, 2024 at 4:40 PM EDT.
There are no upcoming dividends for Unity Biotechnology.
Unity Biotechnology’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Unity Biotechnology.
Unity Biotechnology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.